Table 3:

Cox Regression Analysis of Specific Chronic Health Conditions in Multiple Myeloma Patients Treated with aBMT

Variable	Any grades 3–4 CHC		Subsequent neoplasms		Solid tumor		Melanoma		SCC
	HR (95%CI)	p-value	HR (95% CI)	p-value	HR (95%CI)	p-value	HR (95%CI)	p-value	HR (95%CI)	p-value
Age at aBMT (referent group <60y)
Age at aBMT ≥60y	2.24 (1.7–2.9)	<0.0001	2.12(1.12–4.01)	0.02	1.90(1.0–3.6)	0.05			3.07(0.9–10.6)	0.08
Race/ethnicity (referent group: non-white)
Non-Hispanic white	1.26 (0.98–1.6)	0.08	2.38(1.1–5.17)	0.03	2.23(1.0–4.9)	0.04
Conditioning
TBI ± other	1.59 (0.95–2.7)	0.08
Pre-aBMT therapeutic exposures
Cyclophosphamide			3.36(1.44–7.84)	0.005	3.46(1.5–8.1)	0.004	6.02(1.4–26.1)	0.02
IMiD			3.86(1.49–9.94)	0.005	3.89(1.5–10.1)	0.005	7.9(0.9–68.5)	0.06

Abbreviations: aBMT: Autologous hematopoietic cell transplant, HR: hazard ratio, CI: confidence interval, IMiD: Immunomodulatory drug (Thalidomide or Lenalidomide), TBI: total body irradiation, SCC: squamous cell carcinoma